Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Adrian St. Clair Brown, Ely (GB); Peter Lamb, Oakland, CA (US); and William P. Gallagher, Princeton, NJ (US)
Assigned to Exelixis, Inc., Alameda, CA (US)
Filed by Exelixis, Inc., Alameda, CA (US)
Filed on Nov. 25, 2024, as Appl. No. 18/958,628.
Application 15/617,725 is a division of application No. 14/340,871, filed on Jul. 25, 2014, granted, now 9,809,549, issued on Nov. 7, 2017.
Application 14/340,871 is a division of application No. 13/145,054, granted, now 8,877,776, issued on Nov. 4, 2014, previously published as PCT/US2010/021194, filed on Jan. 15, 2010.
Application 18/958,628 is a continuation of application No. 18/612,538, filed on Mar. 21, 2024, abandoned.
Application 18/612,538 is a continuation of application No. 18/465,462, filed on Sep. 12, 2023, abandoned.
Application 18/465,462 is a continuation of application No. 18/157,568, filed on Jan. 20, 2023, abandoned.
Application 18/157,568 is a continuation of application No. 17/505,275, filed on Oct. 19, 2021, abandoned.
Application 17/505,275 is a continuation of application No. 17/371,372, filed on Jul. 9, 2021, abandoned.
Application 17/371,372 is a continuation of application No. 17/171,752, filed on Feb. 9, 2021, granted, now 11,098,015, issued on Aug. 24, 2021.
Application 17/171,752 is a continuation of application No. 17/149,365, filed on Jan. 14, 2021, granted, now 11,091,440, issued on Aug. 17, 2021.
Application 17/149,365 is a continuation of application No. 17/070,514, filed on Oct. 14, 2020, granted, now 11,091,439, issued on Aug. 17, 2021.
Application 17/070,514 is a continuation of application No. 16/796,250, filed on Feb. 20, 2020, abandoned.
Application 16/796,250 is a continuation of application No. 15/617,725, filed on Jun. 8, 2017, abandoned.
Claims priority of provisional application 61/145,421, filed on Jan. 16, 2009.
Prior Publication US 2025/0084037 A1, Mar. 13, 2025
1. N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (L)-malate salt, wherein said salt is amorphous, characterized by a powder X-ray diffraction pattern substantially in accordance with the pattern shown in FIG. 22.